Shots:
- Polpharma Biologics has launched Ranivisio pre-filled syringe (PFS), a biosimilar version of Lucentis (ranibizumab) in France
- Bioeq AG, a joint venture of Polpharma & Formycon, develops & licenses Ranivisio PFS, with Teva holding exclusive commercialization rights in France. The drug substance is manufactured by Rezon Bio (Polpharma Biologics) in Poland
- Ranibizumab is a recombinant humanized IgG1 mAb fragment that targets & inhibits VEGF-A for the treatment of wet age-related macular degeneration, retinal vein occlusion, & diabetic macular edema
Ref: Polpharma Biologics | Image: Polpharma Biologics | Press Release
Related News:- Polpharma Biologics Enters into Licensing Deals with MS Pharma for Multiple Biosimilar Candidates
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
